# OnCo record imp4927 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/imp4927/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "imp4927" ;
  schema:name "Senaparib (IMP4297)"@en ;
  schema:alternateName "senaparib"@en, "IMP4297"@en, "IMP4927"@en, "Sepalna"@en, "Sepalna" ;
  schema:description "Senaparib is an oral PARP inhibitor from IMPACT Therapeutics tested as maintenance treatment after first-line chemotherapy for advanced ovarian cancer. On 17 September 2026 the EMA's medicines committee recommended EU approval under the name Sepalna; the European Commission's decision is pending."@en ;
  schema:url <https://onco.cc/drugs/imp4927/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=IMP4927>, <https://www.impacttherapeutics.com>, <https://www.ema.europa.eu/en/medicines/human/EPAR/sepalna> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "small molecule (oral PARP inhibitor)" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:targets <https://onco.cc/targets/parp/> ;
  onco:companies <https://onco.cc/companies/impact-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct04169997/> .